W

    Werewolf Therapeutics Inc (HOWL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.94
    -0.00 (-0.24%)

    Market Cap: $45.73M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    -860.54%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.22
    Range$-0.22 - $-0.22
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.22+0.0%
    60d ago$0.00+100.0%
    30d ago$-0.32-45.5%
    7d ago$-0.32-45.5%
    Current$-0.22
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.06
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.06---
    Sep 26EST
    		-$-0.22---
    Jun 26
    Reported Jul 31
    		$0.08N/A+128.57%Beat+120.0%
    Mar 26
    Reported May 7
    		$-0.28$-0.29+5.08%Beat+30.0%
    Dec 25
    Reported Mar 27
    		$-0.17N/A+51.43%Beat+63.0%
    Sep 25
    Reported Nov 4
    		$-0.36$-0.38+5.26%Beat+5.3%
    Jun 25
    Reported Aug 14
    		$-0.40$-0.37-8.11%Miss-5.3%
    Mar 25
    Reported May 8
    		$-0.40$-0.43+6.98%Beat-2.6%
    Dec 24
    Reported Mar 11
    		$-0.46$-0.42-9.52%Miss-39.4%
    Sep 24
    Reported Nov 7
    		$-0.38$-0.39+2.56%Beat-65.2%
    Jun 24
    Reported Aug 8
    		$-0.38$-0.39+2.56%Beat-171.4%
    Mar 24
    Reported May 3
    		$-0.39$-0.34-14.71%Miss-14.7%
    Dec 23
    Reported Mar 7
    		$-0.33$-0.43+23.26%Beat+15.4%
    Sep 23
    Reported Nov 14
    		$-0.23$-0.34+32.35%Beat+42.5%
    Jun 23
    Reported Aug 10
    		$-0.14N/A+65.00%Beat+73.6%
    Mar 23
    Reported May 11
    		$-0.34$-0.46+26.09%Beat+39.3%
    Dec 22
    Reported Mar 23
    		$-0.39$-0.55+29.09%Beat+40.9%
    Sep 22
    Reported Nov 10
    		$-0.40$-0.56+28.57%Beat+21.6%
    Jun 22
    Reported Aug 11
    		$-0.53$-0.60+11.67%Beat+86.1%
    Mar 22
    Reported May 10
    		$-0.56$-0.58+3.45%Beat+99.3%
    Dec 21
    Reported Mar 24
    		$-0.66$-0.53-24.53%Miss-
    Sep 21
    Reported Nov 10
    		$-0.51$-0.46-10.87%Miss-
    Jun 21
    Reported Aug 12
    		$-3.82$-0.28-1264.29%Miss-
    Mar 21
    Reported Apr 30
    		$-83.36$-0.46-18021.74%Miss-

    Key Metrics

    Valuation
    P/E Ratio-1.29EV/EBITDA0.57x
    Price/FCF-1.52xFCF Yield-65.93%
    Profitability
    Profit Margin-164.80%Operating Margin40.60%
    ROE-119.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-3.63x
    Current Ratio2.91xQuick Ratio2.91x
    Trading Statistics
    Beta0.29Avg Volume18.97M
    52-Week High$2.3852-Week Low$0.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.77
    SMA 20$0.58
    SMA 50$0.46
    SMA 200$0.65
    EMA 10$0.81
    EMA 20$0.67
    EMA 50$0.54
    EMA 200$0.68

    MACD

    Line: 0.15Signal: 0.10Hist: 0.05

    ADX

    ADX: 40.1+DI: 51.7-DI: 9.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down16.0
    PSAR$0.42

    Bollinger Bands

    Upper Band$1.10
    Lower Band$0.07
    %B Position17719%(Upper)
    Band Width0.84

    RSI (14-Day)

    Overbought
    81.7

    Momentum Oscillators

    Stoch %K85.7
    Stoch %D86.4
    Williams %R-15.9
    ROC (10d)132.1%
    Momentum0.54
    CCI (20d)94.9
    MFI (14d)95.8

    Volatility Measures

    ATR (14d)$0.09(9.1%)
    StdDev (20d)0.26
    Hist Vol365.7%(High)

    Volume Flow

    VWAP$0.93
    OBV354.1M
    AD Line-237.5M
    CMF (20d)-0.521

    Volume Metrics

    Avg Vol (20d)19.9M
    Vol Ratio0.1x(Low)
    VWMA (20d)$0.80

    Pivot Points

    R3$1.11
    R2$1.07
    R1$1.01
    Pivot Point$0.97
    S1$0.90
    S2$0.86
    S3$0.80

    Advanced Oscillators

    TSI59.02
    Ultimate Osc63.1
    KST875.67

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$21.00M$0$0$0$0$0$-49,000$0$1.14M$742,000$1.50M$5.90M
    Cost of Revenue$0$0$400,000$0$0$0$442,000$0$0$0$460,000$0
    Gross Profit$21.00M$0$-400,000$0$0$0$-967,000$0$1.14M$742,000$1.50M$5.90M
    Operating Expenses$13.84M$13.27M$9.42M$15.73M$17.54M$17.99M$20.35M$17.12M$20.10M$17.90M$14.46M$15.15M
    R&D$6.16M$8.18M$6.93M$11.63M$13.14M$13.12M$15.73M$12.53M$15.27M$12.91M$9.65M$10.84M
    SG&A$7.68M$5.09M$2.48M$4.09M$4.40M$4.87M$4.62M$4.60M$4.83M$5.00M$4.81M$4.31M
    Operating Income$7.16M$-13,271,000$-9,418,000$-15,726,000$-17,542,000$-17,991,000$-20,348,000$-17,124,000$-18,960,000$-17,162,000$-12,962,000$-9,251,000
    Interest Income$277,000$433,000$564,000$697,000$850,000$997,000$1.31M$1.60M$1.79M$1.97M$1.98M$1.97M
    Interest Expense$3.83M$1.37M$1.37M$1.34M$1.30M$1.26M$1.27M$1.24M$1.70M$1.00M$1.01M$1.00M
    Income Before Tax$3.67M$-13,532,000$-8,381,000$-16,370,000$-17,982,000$-18,089,000$-20,400,000$-16,673,000$-17,249,000$-16,193,000$-12,003,000$-8,285,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$3.67M$-13,532,000$-8,381,000$-16,370,000$-17,982,000$-18,089,000$-20,400,000$-16,673,000$-17,249,000$-16,193,000$-12,003,000$-8,285,000
    EBITDA$9.67M$-11,981,000$-7,176,000$-15,324,000$-17,125,000$-17,209,000$-20,000,000$-16,573,000$-16,893,000$-16,323,000$-12,508,000$-8,811,000
    EBIT$7.22M$-12,597,000$-7,576,000$-15,726,000$-17,531,000$-17,823,000$-20,442,000$-17,027,000$-17,347,000$-17,163,000$-12,968,000$-9,256,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HOWL

    News

    Werewolf, Ambros to Merge in All-Stock Deal

    Werewolf Therapeutics Inc. and Ambros Therapeutics Inc. have agreed to an all-stock merger, with the combined entity operating as Ambros Therapeutics and focusing on developing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The deal includes a concurrent private placement of $150 million from leading healthcare investors and is expected to close by the first quarter of 2027. Neridronate has received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations.

    Contract Pharma•8/24/26•
    Neutral

    Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private Placement

    Sidley represented Werewolf Therapeutics in its all-stock merger agreement with Ambros Therapeutics. This merger is coupled with an oversubscribed US$150 million private placement. The combined entity will operate as Ambros Therapeutics, focusing on advancing its neridronate development program for CRPS-1, including an ongoing pivotal Phase 3 clinical trial.

    Legal Desire•8/24/26•
    Bullish

    HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

    Halper Sadeh LLC is investigating the merger of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) and Ambros Therapeutics, Inc. The law firm is concerned that Werewolf shareholders may not be receiving a fair price for their shares and that the sales process may have involved conflicts of interest. Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options.

    The AI Journal•8/24/26•
    Bearish

    Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

    Werewolf Therapeutics and Ambros Therapeutics have announced a definitive merger agreement, creating a Nasdaq-listed, late-stage biotechnology company focused on advancing neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1). The merger is accompanied by an oversubscribed $150 million private placement, expected to fund the company through the CRPS-RISE Phase 3 topline results and NDA submission into the first half of 2029. Neridronate, which has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, aims to be the first FDA-approved treatment for CRPS-1, a debilitating orphan disease.

    GlobeNewswire•8/22/26•
    Bullish

    Press Release: Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement

    Werewolf Therapeutics and Ambros Therapeutics have announced a definitive merger agreement, under which Ambros will become a wholly-owned subsidiary of Werewolf. The combined company will focus on developing Ambros's pipeline of novel biologic immunotherapies for autoimmune diseases, leveraging its proprietary cytokine engineering platform. This merger is supported by an oversubscribed $150 million private placement, expected to close concurrently with the merger.

    Moomoo•8/22/26•
    Bullish

    Frequently Asked Questions About HOWL

    Does HOWL pay dividends?
    Werewolf Therapeutics Inc (HOWL) does not currently pay a regular dividend.
    What is HOWL's market cap?
    Werewolf Therapeutics Inc (HOWL) has a market capitalization of $45.73M with a current stock price of $0.94.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In